Gossamer Bio, Inc. (NASDAQ: GOSS) Investor Securities Class Action Lawsuit 04/03/2020

If you purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), you have certain options and for certain investors are short and strict deadlines running. Deadline: June 2, 2020. NASDAQ: GOSS investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Gossamer Bio
Case Name: 
Gossamer Bio Shareholder Class Action Lawsuit 04/03/2020
Case Status: 
Lawsuit Filed
Affected Securities
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
Class Period Begin: 
Class Period End: 
Court of Filing: 
U.S. District Court for the Southern District of California
Deadline To File for Lead: 

An investor in shares of Gossamer Bio, Inc. (NASDAQ: GOSS) filed a lawsuit in the U.S. District Court for the Southern District of California over alleged violations of Federal Securities Laws by Gossamer Bio, Inc. in connection with certain allegedly false and misleading statements made between February 8, 2019 and December 13, 2019.

San Diego, CA based Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc's most advanced product is its GB001 drug, a DP2 antagonist, in development to treat asthma. In February 2019, Gossamer Bio, Inc conducted its initial public offering ("IPO"), issuing approximately 19.8 million shares of common stock priced at $19.00 per share.

Then, on December 16, 2019, Novartis announced that it was terminating the development of its DP2 antagonist for asthma after it failed a pair of phase 3 clinical trials.
According to the complaint the plaintiff alleges on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the materials supporting Gossamer's IPO, and certain of Gossamer’s post-IPO public filings, misled investors or otherwise omitted material facts relevant to Gossamer’s GB001 drug and its related clinical trials and studies. The plaintiff alleges that the Defendants misrepresented and/or failed to disclose to investors: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis'oral DP2 antagonist; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.